Repositioning Candidate Details
| Candidate ID: | R0091 |
| Source ID: | DB00234 |
| Source Type: | approved; experimental |
| Compound Type: | small molecule |
| Compound Name: | Reboxetine |
| Synonyms: | Reboxetine |
| Molecular Formula: | C19H23NO3 |
| SMILES: | [H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. |
| CAS Number: | 71620-89-8 |
| Molecular Weight: | 313.397 |
| DrugBank Indication: | For the treatment of clinical depression. |
| DrugBank Pharmacology: | Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders. |
| DrugBank MoA: | Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake <i>in vitro</i> to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low <i>in vivo</i> and <i>in vitro</i> affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors. |
| Targets: | Sodium-dependent noradrenaline transporter inhibitor |
| Inclusion Criteria: | Indication associated |
